Adcetris® (brentuximab vedotin) – New indication
February 12, 2025 - Pfizer announced the FDA approval of Adcetris (brentuximab vedotin), in combination with lenalidomide and a rituximab product, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-hematopoietic stem-cell transplantation (HSCT) or chimeric antigen receptor (CAR) T-cell therapy.
Top